EXCLUSION CRITERIA <br/ >Patient will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria: <br/ >1.Patients with severe to critical type of health condition as stratified below: <br/ >2.Clinical stratification: <br/ >3.Severe type: meeting any of the following criteria: <br/ >(a)Respiratory distress, RRâ?¥30 times/min <br/ >(b)Finger oxygen saturation â?¤90% in resting state <br/ >(c)Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation (FiO2)â?¤300mmHg. <br/ >4.Critical type: meeting any of the following criteria: <br/ >(a)Respiratory failure occurs and mechanical ventilation is required, <br/ >(b)Patients go into shock, <br/ >(c) ICU is needed for other organ failure. <br/ >5.Other viral pneumonia Patients who can not take food or drugs due to coma or intestinal obstruction <br/ >6.Consumption of other oral probiotic supplements during the trial <br/ >7.Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc. <br/ >8.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >9.Allergic to systemic enzyme supplements. <br/ >10.Imminent death in the opinion of the clinical team <br/ >11.Patients with Hb less than 8 mg/dl <br/ >13.Patients who have participated in any other clinical study within 2 weeks prior to randomization, <br/ >14.The investigator concludes that the patient is not suitable for the study. <br/ >

EXCLUSION CRITERIA <br/ >Patient will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria: <br/ >1.Patients with severe to critical type of health condition as stratified below: <br/ >2.Clinical stratification: <br/ >3.Severe type: meeting any of the following criteria: <br/ >(a)Respiratory distress, RRâ?¥30 times/min <br/ >(b)Finger oxygen saturation â?¤90% in resting state <br/ >(c)Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation (FiO2)â?¤300mmHg. <br/ >4.Critical type: meeting any of the following criteria: <br/ >(a)Respiratory failure occurs and mechanical ventilation is required, <br/ >(b)Patients go into shock, <br/ >(c) ICU is needed for other organ failure. <br/ >5.Other viral pneumonia Patients who can not take food or drugs due to coma or intestinal obstruction <br/ >6.Consumption of other oral probiotic supplements during the trial <br/ >7.Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc. <br/ >8.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >9.Allergic to systemic enzyme supplements. <br/ >10.Imminent death in the opinion of the clinical team <br/ >11.Patients with Hb less than 8 mg/dl <br/ >13.Patients who have participated in any other clinical study within 2 weeks prior to randomization, <br/ >14.The investigator concludes that the patient is not suitable for the study. <br/ >

N/A

N/A

EXCLUSION CRITERIA <br/ >Patient will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria: <br/ >1.Patients with severe to critical type of health condition as stratified below: <br/ >2.Clinical stratification: <br/ >3.Severe type: meeting any of the following criteria: <br/ >(a)Respiratory distress, RRâ?¥30 times/min <br/ >(b)Finger oxygen saturation â?¤90% in resting state <br/ >(c)Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation (FiO2)â?¤300mmHg. <br/ >4.Critical type: meeting any of the following criteria: <br/ >(a)Respiratory failure occurs and mechanical ventilation is required, <br/ >(b)Patients go into shock, <br/ >(c) ICU is needed for other organ failure. <br/ >5.Other viral pneumonia Patients who can not take food or drugs due to coma or intestinal obstruction <br/ >6.Consumption of other oral probiotic supplements during the trial <br/ >7.Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc. <br/ >8.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >9.Allergic to systemic enzyme supplements. <br/ >10.Imminent death in the opinion of the clinical team <br/ >11.Patients with Hb less than 8 mg/dl <br/ >13.Patients who have participated in any other clinical study within 2 weeks prior to randomization, <br/ >14.The investigator concludes that the patient is not suitable for the study. <br/ >

EXCLUSION CRITERIA <br/ >Patient will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria: <br/ >1.Patients with severe to critical type of health condition as stratified below: <br/ >2.Clinical stratification: <br/ >3.Severe type: meeting any of the following criteria: <br/ >(a)Respiratory distress, RRâ?¥30 times/min <br/ >(b)Finger oxygen saturation â?¤90% in resting state <br/ >(c)Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation (FiO2)â?¤300mmHg. <br/ >4.Critical type: meeting any of the following criteria: <br/ >(a)Respiratory failure occurs and mechanical ventilation is required, <br/ >(b)Patients go into shock, <br/ >(c) ICU is needed for other organ failure. <br/ >5.Other viral pneumonia Patients who can not take food or drugs due to coma or intestinal obstruction <br/ >6.Consumption of other oral probiotic supplements during the trial <br/ >7.Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc. <br/ >8.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >9.Allergic to systemic enzyme supplements. <br/ >10.Imminent death in the opinion of the clinical team <br/ >11.Patients with Hb less than 8 mg/dl <br/ >13.Patients who have participated in any other clinical study within 2 weeks prior to randomization, <br/ >14.The investigator concludes that the patient is not suitable for the study. <br/ >